Full history for every metric is available with a Kvantra account
Medesis Pharma S.A. (ALMDP.PA)
Key financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | €m | -4 | |||||
| Net profit | €m | -1 | -2 | -1 | -3 | -3 | -4 |
| EPS reported | € | -0.80 | |||||
| Operating cashflow per share | € | 0.00 | |||||
| Capex per share | € | 0.00 | |||||
| FCF per share | € | 0.00 | |||||
| Free cash flow | €m | 0 | |||||
| Net debt | €m | 1 | |||||
| Book value equity | €m | -4 | |||||
| Book value per share | € | -0.91 | |||||
| Number of shares | m | 4.96 | |||||
| DPS (TTM paid) | € | 0.00 |
Financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | -0.96 | |||||
| P/S LTM | x | 14.35 | |||||
| P/FCF LTM | x | 0.00 | |||||
| EV/EBITDA LTM | x | -1.42 | |||||
| EV/Sales LTM | x | 18.21 | |||||
| Earnings Yield LTM | % | -91.96% | |||||
| FCF Yield | % | 0.00% | |||||
| Quality | |||||||
| ROE | % | 87.99% | |||||
| ROIC | % | 412.18% | |||||
| Operating margin | % | -1409.6% | |||||
| Gross margin | % | -888.16% | |||||
| FCF/Sales | % | 0.00% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | +534.36% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | 0.00 | |||||
| Net Debt/EBITDA | x | -0.30 | |||||
| EBIT/Net interest | x | -16.60 | |||||
| Net debt/market cap | % | 26.90% | |||||
| Net debt/Equity | x | -0.26 | |||||
| Gross debt/equity | x | -0.27 | |||||
Company overview
Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to creating orally delivered molecular drug therapies aimed at critical medical conditions lacking effective treatments. The company's pipeline features several innovative compounds, including NanoLithium (NP03), which is currently undergoing clinical trials for Alzheimer's disease, and NanosiRNA DH, targeting Huntington's Disease. Medesis Pharma also develops NU01 Plutonium and NU02 Cesium for nuclear decorporation, alongside NP02 – NanoManganese, a radioprotection medication designed for individuals exposed to radiation from nuclear incidents. Furthermore, their portfolio encompasses NanosiRNA COVID-19, an antiviral solution for various viral infections, and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for oncological applications. Established in 2003, the enterprise operates from its headquarters in Montpellier, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Medesis Pharma S.A. (ALMDP.PA)
Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to creating orally delivered molecular drug therapies aimed at critical medical conditions lacking effective treatments. The company's pipeline features several innovative compounds, including NanoLithium (NP03), which is currently undergoing clinical trials for Alzheimer's disease, and NanosiRNA DH, targeting Huntington's Disease. Medesis Pharma also develops NU01 Plutonium and NU02 Cesium for nuclear decorporation, alongside NP02 – NanoManganese, a radioprotection medication designed for individuals exposed to radiation from nuclear incidents. Furthermore, their portfolio encompasses NanosiRNA COVID-19, an antiviral solution for various viral infections, and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for oncological applications. Established in 2003, the enterprise operates from its headquarters in Montpellier, France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free